Cabot Corporation (CBT) is a Chemicals - Specialty company in the Basic Materials sector, currently trading at $74.57. It has a SharesGrow Score of 64/100, indicating a above average investment profile with 3 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of CBT = $176.63 (+136.9% from the current price, the stock appears undervalued). Analyst consensus target is CBT = $78 (+4.6% upside).
Valuation: CBT trades at a trailing Price-to-Earnings (P/E) of 12.7 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 1.26.
Financials: revenue is $3.7B, -4.8%/yr average growth. Net income is $331M, growing at +28.5%/yr. Net profit margin is 8.9% (thin). Gross margin is 25.3% (+4.8 pp trend).
Balance sheet: total debt is $1.2B against $1.6B equity (Debt-to-Equity (D/E) ratio 0.78, moderate). Current ratio is 1.61 (strong liquidity). Debt-to-assets is 31.8%. Total assets: $3.8B.
Analyst outlook: 7 / 15 analysts rate CBT as buy (47%) — mixed sentiment.
SharesGrow 7-Criteria breakdown: Value 72/100 (Pass), Growth 58/100 (Partial), Past 100/100 (Pass), Health 83/100 (Pass), Moat 53/100 (Partial), Future 34/100 (Fail), Income 45/100 (Partial).
